Care Manager providing BAFIERTAM® access support for Multiple Sclerosis patients.

Access and Support That Makes
a Difference

Care Manager providing BAFIERTAM® access support for Multiple Sclerosis patients.

We know that life-changing treatments need a support
system which is tailored to the unique challenges your patients
might be facing.

Cycle Vita^TM is here for your patients, for life

Bridge Program*

A free supply of BAFIERTAM to allow patients to start therapy immediately while Cycle Vita assists with reimbursement research. The Bridge Program is also available to existing patients who are temporarily experiencing disruption in therapy due to insurance coverage.

Bridge duration is driven by insurance coverage and the active pursuit of insurance coverage by the patient’s healthcare provider.

Co-Pay Assistance Program*

Commercially insured eligible patients may pay as little as $0.

Reimbursement Research Support*

Including Benefit Investigation and assistance with Prior Authorization, as necessary.

Appeals*

Where an appeal is needed, the experienced team at Cycle Vita will work with your patient’s payor to understand the requirements and help with reimbursement gaps.

Prescription Renewal Support*

Cycle Vita will proactively remind you when your patients’ BAFIERTAM prescriptions need to be renewed, to ensure an uninterrupted supply of therapy.

Medication Adherence Support*

Clinical Education Managers can provide disease state and medication training to facilitate adherence.

If you have any questions the Cycle Vita team is only a phone call away, please call us at 888-360-8482 or email hello@cyclevita.life

*Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at 888-360-8482.

Patient holding BAFIERTAM® support pamphlet for Multiple Sclerosis patients.

Patient holding BAFIERTAM® support pamphlet for Multiple Sclerosis patients.

Resources to help your
office

Indication and
Important Safety Information

Indication and Usage

BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Contraindications

BAFIERTAM is contraindicated in patients

With known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM. Reactions may include anaphylaxis or angioedema.
Taking dimethyl fumarate or diroximel fumarate.

Warnings and Precautions

Anaphylaxis and Angioedema

BAFIERTAM can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in patients taking dimethyl fumarate (the prodrug of BAFIERTAM) have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue BAFIERTAM and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema.

Progressive Multifocal Leukoencephalopathy (PML)

PML has occurred in patients with MS treated with dimethyl fumarate (the prodrug of BAFIERTAM). PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received dimethyl fumarate (the prodrug of BAFIERTAM) for 4 years while enrolled in a clinical trial.
PML has also occurred in patients taking dimethyl fumarate in the postmarketing setting in the presence of lymphopenia (<0.9x10⁹/L). While the role of lymphopenia in these cases is uncertain, the PML cases have occurred predominantly in patients with lymphocyte counts <0.8x10⁹/L persisting for more than 6 months.
At the first sign or symptom suggestive of PML, withhold BAFIERTAM and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present.

Herpes Zoster and Other Serious Opportunistic Infections

Serious cases of herpes zoster have occurred with dimethyl fumarate (the prodrug of BAFIERTAM), including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis. These events may occur at any time during treatment. Monitor patients on BAFIERTAM for signs and symptoms of herpes zoster. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered.
Other serious opportunistic infections have occurred with dimethyl fumarate (the prodrug of BAFIERTAM), including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections. These infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear. Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.
Consider withholding BAFIERTAM treatment in patients with herpes zoster or other serious infections until the infection has resolved.

Lymphopenia

BAFIERTAM may decrease lymphocyte counts. In the MS placebo-controlled trials with dimethyl fumarate (the prodrug of BAFIERTAM), mean lymphocyte counts decreased by approximately 30% during the first year of treatment with dimethyl fumarate and then remained stable. Four weeks after stopping dimethyl fumarate, mean lymphocyte counts increased, but did not return to baseline. Six percent (6%) of dimethyl fumarate patients and <1% of placebo patients experienced lymphocyte counts <0.5x10⁹/L (lower limit of normal 0.91x10⁹/L). The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with dimethyl fumarate or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10⁹/L or <0.5x10⁹/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10⁹/L for 3.5 years).
In controlled and uncontrolled clinical trials with dimethyl fumarate, 2% of patients experienced lymphocyte counts <0.5x10⁹/L for at least 6 months, and in this group, the majority of lymphocyte counts remained <0.5x10⁹/L with continued therapy. Neither BAFIERTAM nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts.
Obtain a CBC, including lymphocyte count, before initiating treatment with BAFIERTAM, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of BAFIERTAM in patients with lymphocyte counts less than 0.5x10⁹/L persisting for more than 6 months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if BAFIERTAM is discontinued or interrupted because of lymphopenia. Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart BAFIERTAM should be individualized based on clinical circumstances.

Liver Injury

Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate (the prodrug of BAFIERTAM) in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients.
Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials.
Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating BAFIERTAM and during treatment, as clinically indicated. Discontinue BAFIERTAM if clinically significant liver injury induced by BAFIERTAM is suspected.

Flushing

BAFIERTAM may cause flushing (e.g., warmth, redness, itching, and/or burning sensation). In clinical trials of dimethyl fumarate (the prodrug of BAFIERTAM), 40% of dimethyl fumarate-treated patients experienced flushing. Studies with dimethyl fumarate show that administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to dosing may reduce the incidence or severity of flushing. In the BAFIERTAM studies, the presence of food did not impact the incidence of flushing.

Serious Gastrointestinal Reactions

Serious gastrointestinal reactions, including perforation, ulceration, hemorrhage, and obstruction, some with fatal outcomes, have been reported in the postmarketing setting with the use of fumaric acid esters, including dimethyl fumarate, with or without concomitant aspirin use. The majority of these events have occurred within 6 months of fumaric acid ester treatment initiation. In controlled clinical trials, the incidence of serious gastrointestinal adverse events was 1% in patients treated with dimethyl fumarate; these events, none of which were fatal, included vomiting (0.3%) and abdominal pain (0.3%)
Monitor patients, promptly evaluate, and discontinue BAFIERTAM for new or worsening severe gastrointestinal signs and symptoms.

Adverse Reactions

The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate (the prodrug of BAFIERTAM) were flushing, abdominal pain, diarrhea, and nausea.
Gastrointestinal adverse reactions: Dimethyl fumarate caused GI events (e.g., nausea, vomiting, diarrhea, abdominal pain, and dyspepsia). In clinical trials, the incidence of GI events was higher early in the course of treatment (primarily during the first month) and usually decreased over time in patients treated with dimethyl fumarate compared with placebo. Four percent (4%) of patients treated with dimethyl fumarate and less than 1% of patients on placebo discontinued due to gastrointestinal events. The incidence of serious GI events was 1% in clinical trial patients treated with dimethyl fumarate; these events, none of which were fatal, included vomiting (0.3%) and abdominal pain (0.3%).
Hepatic transaminases: An increased incidence of elevations of hepatic transaminases in patients treated with dimethyl fumarate in clinical trials was seen primarily during the first 6 months of treatment, and most patients with elevations had levels <3 times the upper limit of normal (ULN). Elevations of alanine aminotransferase and aspartate aminotransferase to ≥3 times the ULN occurred in a small number of patients treated with both dimethyl fumarate and in patients on placebo, and were balanced between the groups. There were no elevations in transaminases ≥3 times the ULN with concomitant elevations in total bilirubin >2 times the ULN. Discontinuations due to elevated hepatic transaminases were <1%, and were similar in patients treated with dimethyl fumarate or placebo.
Eosinophilia adverse reactions: A transient increase in mean eosinophil counts was seen during the first 2 months of therapy with dimethyl fumarate.

Please see the full Prescribing Information.

Indication and Important Safety Information

¿Qué es BAFIERTAM® (monometil fumarato)?

BAFIERTAM es un medicamento con receta utilizado para tratar formas recidivantes de la esclerosis múltiple (EM), para incluir el síndrome clínico aislado, la enfermedad remitente recurrente y la enfermedad progresiva secundaria activa en adultos.
Se desconoce si BAFIERTAM es seguro y eficaz en niños.

¿Quién no debe tomar BAFIERTAM?

No tome BAFIERTAM si: ha tenido una reacción alérgica (como ronchas, urticaria, hinchazón de la cara, labios, boca o lengua, o dificultad para respirar) a monometil fumarato, dimetil fumarato, diroximel fumarato o cualquiera de los ingredientes de BAFIERTAM.
No tome BAFIERTAM si está tomando dimetil fumarato o diroximel fumarato.

Antes de tomar y mientras toma BAFIERTAM, informe a su médico sobretodas sus afecciones médicas, incluido si:

Tiene problemas hepáticos.
Tiene o ha tenido un recuento bajo de glóbulos blancos o una infección.
Está embarazada o planea quedar embarazada. Se desconoce si BAFIERTAM dañará al bebé en gestación.
Está en periodo de lactancia o planea amamantar. Se desconoce si BAFIERTAM pasa a la leche materna. Hable con su proveedor de atención médica sobre la mejor manera de alimentar a su bebé mientras utiliza BAFIERTAM.

Informe a su médico sobre todos los medicamentos que toma, incluidos los medicamentos con receta y de venta libre, vitaminas y suplementos a base de hierbas.

¿Cuáles son los posibles efectos secundarios de BAFIERTAM?

BAFIERTAM puede causar efectos secundarios graves, incluidos:

Reacción alérgica (como ronchas, urticaria, hinchazón de la cara, labios, boca o lengua, o dificultad para respirar). Deje de tomar BAFIERTAM y busque asistencia médica de emergencia inmediatamente si tiene cualquiera de estos síntomas.
LMP (leucoencefalopatía multifocal progresiva) una infección cerebral rara que generalmente provoca la muerte o discapacidad grave durante un periodo de semanas o meses.
- Informe a su médico inmediatamente si presenta alguno de estos síntomas de LMP:
  - debilidad en un lado del cuerpo que empeora
  - torpeza en brazos o piernas
  - problemas de visión
  - cambios en el pensamiento y la memoria
  - confusión
  - cambios de personalidad
Infecciones por herpes zóster (culebrilla), incluidas las infecciones del sistema nervioso central.
Otras infecciones graves.
Disminuciones del recuento de glóbulos blancos. Su médico debe hacerle un análisis de sangre para comprobar su recuento de glóbulos blancos antes de comenzar el tratamiento con BAFIERTAM y mientras esté en terapia. Debe hacerse análisis de sangre después de 6 meses de tratamiento y cada 6 a 12 meses en lo sucesivo.
Problemas hepáticos. BAFIERTAM puede causar problemas hepáticos graves que pueden provocar insuficiencia hepática, un trasplante de hígado o la muerte. Su médico debe hacerle análisis de sangre para comprobar su función hepática antes de empezar a tomar BAFIERTAM y durante el tratamiento si es necesario.
- Informe a su médico inmediatamente si presenta alguno de estos síntomas de un problema hepático durante el tratamiento:
  - cansancio intenso
  - pérdida del apetito
  - dolor en el lado derecho del estómago
  - tiene orina oscura o marrón (color del té)
  - coloración amarillenta de la piel o de la parte blanca de los ojos

Los efectos secundarios más frecuentes de BAFIERTAM incluyen:

Rubefacción, enrojecimiento, comezón o erupción.
Náuseas, vómitos, diarrea, dolor de estómago o indigestión.
La rubefacción y los problemas de estómago son las reacciones más frecuentes, especialmente al inicio del tratamiento, y pueden disminuir con el tiempo. Llame a su médico si tiene alguno de estos síntomas y le molestan o no desaparecen. Pregunte a su médico si tomar aspirina antes de tomar BAFIERTAM puede reducir la rubefacción.

Estos no son todos los posibles efectos secundarios de BAFIERTAM. Llame a su médico para obtener consejo sobre los efectos secundarios. Puede reportar los efectos secundarios a la FDA al 1-800-FDA-1088. Para obtener más información visite dailymed.nlm.nih.gov.

Consulte la Información de prescripción e Información para el paciente.

Esta información no sustituye la consulta con su médico sobre su condición médica o su tratamiento.

Indication and
Important Safety Information

Indication and Usage

BAFIERTAM is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Contraindications

BAFIERTAM is contraindicated in patients

With known hypersensitivity to monomethyl fumarate, dimethyl fumarate, diroximel fumarate, or to any of the excipients of BAFIERTAM. Reactions may include anaphylaxis or angioedema.
Taking dimethyl fumarate or diroximel fumarate.

Warnings and Precautions

Anaphylaxis and Angioedema

BAFIERTAM can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms in patients taking dimethyl fumarate (the prodrug of BAFIERTAM) have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue BAFIERTAM and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema.

Progressive Multifocal Leukoencephalopathy (PML)

PML has occurred in patients with MS treated with dimethyl fumarate (the prodrug of BAFIERTAM). PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received dimethyl fumarate (the prodrug of BAFIERTAM) for 4 years while enrolled in a clinical trial.
PML has also occurred in patients taking dimethyl fumarate in the postmarketing setting in the presence of lymphopenia (<0.9x10⁹/L). While the role of lymphopenia in these cases is uncertain, the PML cases have occurred predominantly in patients with lymphocyte counts <0.8x10⁹/L persisting for more than 6 months.
At the first sign or symptom suggestive of PML, withhold BAFIERTAM and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
Magnetic resonance imaging (MRI) findings may be apparent before clinical signs or symptoms. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present.

Herpes Zoster and Other Serious Opportunistic Infections

Serious cases of herpes zoster have occurred with dimethyl fumarate (the prodrug of BAFIERTAM), including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis. These events may occur at any time during treatment. Monitor patients on BAFIERTAM for signs and symptoms of herpes zoster. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered.
Other serious opportunistic infections have occurred with dimethyl fumarate (the prodrug of BAFIERTAM), including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections. These infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear. Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment.
Consider withholding BAFIERTAM treatment in patients with herpes zoster or other serious infections until the infection has resolved.

Lymphopenia

BAFIERTAM may decrease lymphocyte counts. In the MS placebo-controlled trials with dimethyl fumarate (the prodrug of BAFIERTAM), mean lymphocyte counts decreased by approximately 30% during the first year of treatment with dimethyl fumarate and then remained stable. Four weeks after stopping dimethyl fumarate, mean lymphocyte counts increased, but did not return to baseline. Six percent (6%) of dimethyl fumarate patients and <1% of placebo patients experienced lymphocyte counts <0.5x10⁹/L (lower limit of normal 0.91x10⁹/L). The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with dimethyl fumarate or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x10⁹/L or <0.5x10⁹/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x10⁹/L for 3.5 years).
In controlled and uncontrolled clinical trials with dimethyl fumarate, 2% of patients experienced lymphocyte counts <0.5x10⁹/L for at least 6 months, and in this group, the majority of lymphocyte counts remained <0.5x10⁹/L with continued therapy. Neither BAFIERTAM nor dimethyl fumarate have been studied in patients with preexisting low lymphocyte counts.
Obtain a CBC, including lymphocyte count, before initiating treatment with BAFIERTAM, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of BAFIERTAM in patients with lymphocyte counts less than 0.5x10⁹/L persisting for more than 6 months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if BAFIERTAM is discontinued or interrupted because of lymphopenia. Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart BAFIERTAM should be individualized based on clinical circumstances.

Liver Injury

Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate (the prodrug of BAFIERTAM) in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients.
Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials.
Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating BAFIERTAM and during treatment, as clinically indicated. Discontinue BAFIERTAM if clinically significant liver injury induced by BAFIERTAM is suspected.

Flushing

BAFIERTAM may cause flushing (e.g., warmth, redness, itching, and/or burning sensation). In clinical trials of dimethyl fumarate (the prodrug of BAFIERTAM), 40% of dimethyl fumarate-treated patients experienced flushing. Studies with dimethyl fumarate show that administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to dosing may reduce the incidence or severity of flushing. In the BAFIERTAM studies, the presence of food did not impact the incidence of flushing.

Serious Gastrointestinal Reactions

Serious gastrointestinal reactions, including perforation, ulceration, hemorrhage, and obstruction, some with fatal outcomes, have been reported in the postmarketing setting with the use of fumaric acid esters, including dimethyl fumarate, with or without concomitant aspirin use. The majority of these events have occurred within 6 months of fumaric acid ester treatment initiation. In controlled clinical trials, the incidence of serious gastrointestinal adverse events was 1% in patients treated with dimethyl fumarate; these events, none of which were fatal, included vomiting (0.3%) and abdominal pain (0.3%)
Monitor patients, promptly evaluate, and discontinue BAFIERTAM for new or worsening severe gastrointestinal signs and symptoms.

Adverse Reactions

The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for dimethyl fumarate (the prodrug of BAFIERTAM) were flushing, abdominal pain, diarrhea, and nausea.
Gastrointestinal adverse reactions: Dimethyl fumarate caused GI events (e.g., nausea, vomiting, diarrhea, abdominal pain, and dyspepsia). In clinical trials, the incidence of GI events was higher early in the course of treatment (primarily during the first month) and usually decreased over time in patients treated with dimethyl fumarate compared with placebo. Four percent (4%) of patients treated with dimethyl fumarate and less than 1% of patients on placebo discontinued due to gastrointestinal events. The incidence of serious GI events was 1% in clinical trial patients treated with dimethyl fumarate; these events, none of which were fatal, included vomiting (0.3%) and abdominal pain (0.3%).
Hepatic transaminases: An increased incidence of elevations of hepatic transaminases in patients treated with dimethyl fumarate in clinical trials was seen primarily during the first 6 months of treatment, and most patients with elevations had levels <3 times the upper limit of normal (ULN). Elevations of alanine aminotransferase and aspartate aminotransferase to ≥3 times the ULN occurred in a small number of patients treated with both dimethyl fumarate and in patients on placebo, and were balanced between the groups. There were no elevations in transaminases ≥3 times the ULN with concomitant elevations in total bilirubin >2 times the ULN. Discontinuations due to elevated hepatic transaminases were <1%, and were similar in patients treated with dimethyl fumarate or placebo.
Eosinophilia adverse reactions: A transient increase in mean eosinophil counts was seen during the first 2 months of therapy with dimethyl fumarate.

Please see the full Prescribing Information.

Indication and Important Safety Information

¿Qué es BAFIERTAM® (monometil fumarato)?

BAFIERTAM es un medicamento con receta utilizado para tratar formas recidivantes de la esclerosis múltiple (EM), para incluir el síndrome clínico aislado, la enfermedad remitente recurrente y la enfermedad progresiva secundaria activa en adultos.
Se desconoce si BAFIERTAM es seguro y eficaz en niños.

¿Quién no debe tomar BAFIERTAM?

No tome BAFIERTAM si: ha tenido una reacción alérgica (como ronchas, urticaria, hinchazón de la cara, labios, boca o lengua, o dificultad para respirar) a monometil fumarato, dimetil fumarato, diroximel fumarato o cualquiera de los ingredientes de BAFIERTAM.
No tome BAFIERTAM si está tomando dimetil fumarato o diroximel fumarato.

Antes de tomar y mientras toma BAFIERTAM, informe a su médico sobretodas sus afecciones médicas, incluido si:

Tiene problemas hepáticos.
Tiene o ha tenido un recuento bajo de glóbulos blancos o una infección.
Está embarazada o planea quedar embarazada. Se desconoce si BAFIERTAM dañará al bebé en gestación.
Está en periodo de lactancia o planea amamantar. Se desconoce si BAFIERTAM pasa a la leche materna. Hable con su proveedor de atención médica sobre la mejor manera de alimentar a su bebé mientras utiliza BAFIERTAM.

Informe a su médico sobre todos los medicamentos que toma, incluidos los medicamentos con receta y de venta libre, vitaminas y suplementos a base de hierbas.

¿Cuáles son los posibles efectos secundarios de BAFIERTAM?

BAFIERTAM puede causar efectos secundarios graves, incluidos:

Reacción alérgica (como ronchas, urticaria, hinchazón de la cara, labios, boca o lengua, o dificultad para respirar). Deje de tomar BAFIERTAM y busque asistencia médica de emergencia inmediatamente si tiene cualquiera de estos síntomas.
LMP (leucoencefalopatía multifocal progresiva) una infección cerebral rara que generalmente provoca la muerte o discapacidad grave durante un periodo de semanas o meses.
- Informe a su médico inmediatamente si presenta alguno de estos síntomas de LMP:
  - debilidad en un lado del cuerpo que empeora
  - torpeza en brazos o piernas
  - problemas de visión
  - cambios en el pensamiento y la memoria
  - confusión
  - cambios de personalidad
Infecciones por herpes zóster (culebrilla), incluidas las infecciones del sistema nervioso central.
Otras infecciones graves.
Disminuciones del recuento de glóbulos blancos. Su médico debe hacerle un análisis de sangre para comprobar su recuento de glóbulos blancos antes de comenzar el tratamiento con BAFIERTAM y mientras esté en terapia. Debe hacerse análisis de sangre después de 6 meses de tratamiento y cada 6 a 12 meses en lo sucesivo.
Problemas hepáticos. BAFIERTAM puede causar problemas hepáticos graves que pueden provocar insuficiencia hepática, un trasplante de hígado o la muerte. Su médico debe hacerle análisis de sangre para comprobar su función hepática antes de empezar a tomar BAFIERTAM y durante el tratamiento si es necesario.
- Informe a su médico inmediatamente si presenta alguno de estos síntomas de un problema hepático durante el tratamiento:
  - cansancio intenso
  - pérdida del apetito
  - dolor en el lado derecho del estómago
  - tiene orina oscura o marrón (color del té)
  - coloración amarillenta de la piel o de la parte blanca de los ojos

Los efectos secundarios más frecuentes de BAFIERTAM incluyen:

Rubefacción, enrojecimiento, comezón o erupción.
Náuseas, vómitos, diarrea, dolor de estómago o indigestión.
La rubefacción y los problemas de estómago son las reacciones más frecuentes, especialmente al inicio del tratamiento, y pueden disminuir con el tiempo. Llame a su médico si tiene alguno de estos síntomas y le molestan o no desaparecen. Pregunte a su médico si tomar aspirina antes de tomar BAFIERTAM puede reducir la rubefacción.

Estos no son todos los posibles efectos secundarios de BAFIERTAM. Llame a su médico para obtener consejo sobre los efectos secundarios. Puede reportar los efectos secundarios a la FDA al 1-800-FDA-1088. Para obtener más información visite dailymed.nlm.nih.gov.

Consulte la Información de prescripción e Información para el paciente.

Esta información no sustituye la consulta con su médico sobre su condición médica o su tratamiento.

References: 1. Palte MJ, Wehr A, Tawa M, et al. Improving the gastrointestinal tolerability of fumaric acid esters: early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther. 2019;36(11):3154-3165. 2. BAFIERTAM. Prescribing Information. Banner Life Sciences LLC; 2021. 3. Lategan TW, Wang L, Sprague TN, Rousseau FS. Pharmacokinetics and bioavailability of monomethyl fumarate following a single oral dose of BAFIERTAM™ (monomethyl fumarate) or Tecfidera® (dimethyl fumarate). CNS Drugs. 2021;35:567-574. doi.org/10.1007/s40263-021-00799-9 4. Tecfidera. Prescribing Information. Biogen Inc; 2022. 5. Vumerity. Prescribing Information. Biogen Inc; 2022. 6. Wynn D, Lategan TW, Sprague TN, Rousseau FS, Fox EJ. Monomethyl fumarate has better gastrointestinal tolerability profile compared with dimethyl fumarate. Mult Scler Relat Disord. 2020;45:102335. doi.org:10.1016/j.msard.2020.102335 7. Ansari NN, Tarameshlu M, Ghelichi L. Dysphagia in multiple sclerosis patients: diagnostic and evaluation strategies. Degener Neurol Neuromuscul Dis. 2020;10:15-28. doi: 10.2147/DNND.S198659